Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00786201 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
NCT00786201 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 126 participants.
The verdict
NCT00786201, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
Study Summary
The experimental drug CNTO 888 is currently being studied in cancer patients with solid tumors and this study is the first to use this drug for patients with idiopathic pulmonary fibrosis (IPF). This study tests the safety and effectiveness of CNTO 888 compared to placebo. The purpose of this research study is to determine if CNTO 888 is safe and to determine its effects (good and bad) on patients with IPF. The study will be conducted at approximately 28 sites globally. Patients can remain on usual, accepted treatment for IPF while enrolled in the study. Participating in other experimental studies or taking other experimental medications while participating in this study will not be allowed.
Interventions
- DRUG Placebo
- DRUG CNTO 888 1 mg/kg
- DRUG CNTO 888 5 mg/kg
- DRUG CNTO 888 15 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2008-12 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00786201
The ClinicalTrials.gov registry entry for NCT00786201 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00786201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00786201 about?
NCT00786201 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)". The experimental drug CNTO 888 is currently being studied in cancer patients with solid tumors and this study is the first to use this drug for patients with idiopathic pulmonary fibrosis (IPF). This study tests the safety and effectiveness of CNTO 888 compared to placebo. The purpose of this resear...
What is the current status of trial NCT00786201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2008-12. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00786201?
The interventions under investigation include: Placebo (DRUG), CNTO 888 1 mg/kg (DRUG), CNTO 888 5 mg/kg (DRUG), CNTO 888 15 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00786201?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.